Botanical and Plant-Derived Drugs: Global Markets
BCC Research
February 1, 2009 SKU: WA2207945
|
|
This report:
- Identifies and classifies the plant-derived drugs that have been commercialized to date
- Contains forecasts for the global volume and value of plant-derived drug shipments and their markets through 2013
- Analyzes the historical and current volume and value of shipments of each of these drugs in specified geographical markets
- Identifies and evaluates the impact of factors that will drive future demand for plant-derived drugs
- Describes plant-derived drugs that are currently in the clinical testing or approvals stage and assesses the probability that they will be commercialized successfully in the next 5 years
- Profiles the leading manufacturers of plant-derived drugs and the firms that may become important players in the next 5 years.
|
- CHAPTER 1: INTRODUCTION
- STUDY BACKGROUND
- STUDY GOAL AND OBJECTIVES
- INTENDED AUDIENCE
- SCOPE OF REPORT
- METHODOLOGY AND INFORMATION SOURCES
- COMMERCIAL DRUGS
- DEVELOPMENTAL DRUGS
- TABLE 1 FDA APPROVAL PROCESS FOR NEW DRUGS
- ANALYST CREDENTIALS
- RELATED BCC PUBLICATIONS
- BCC ONLINE SERVICES
- DISCLAIMER
- CHAPTER 2: SUMMARY
- SUMMARY TABLE GLOBAL FORECAST FOR BOTANICAL* AND PLANT-DERIVED DRUGS, THROUGH 2013 ($ BILLIONS)
- SUMMARY FIGURE GLOBAL FORECAST FOR BOTANICAL* AND PLANT-DERIVED DRUGS, THROUGH 2013 ($ BILLIONS)
- CHAPTER 3: OVERVIEW
- BRIEF HISTORY OF PLANT-DERIVED MEDICINES
- BRIEF HISTORY OF PLANT-… (CONTINUED)
- TABLE 2 KEY DATES IN BOTANICAL MEDICINE
- TABLE 3 WELL KNOWN PLANT-DERIVED DRUGS
- OPPORTUNITY LIES BEYOND WHAT’S KNOWN
- FIGURE 1 COMPOSITION OF FDA-APPROVED NATURAL-DERIVED COMPOUNDS IN U.S. (2000-2005)* (%)
- KEY DRIVERS
- KEY CHALLENGES
- SIGNS OF INDUSTRY INVESTMENT
- TABLE 4 SWOT ANALYSIS ON BOTANICAL DRUG DEVELOPMENT
- TABLE 5 KEY SIGNS OF INVESTMENT IN BOTANICAL AND OTHER PLANT-DERIVED DRUGS
- BOTANICAL DRUGS DEFINED
- UNDERSTANDING THE REGULATORY PROCESS
- TABLE 6 DISTINCTIONS AMONG PRODUCTS THAT USE PLANTS MEDICINALLY
- THE FIRST APPROVED BOTANICAL
- A GROWING PIPELINE
- FIGURE 2 INDS IN THE FDA BY THERAPEUTIC AREA (NUMBER)
- OVERALL PHARMA LANDSCAPE
- TABLE 7 TOP PHARMA COMPANIES BY REVENUE, 2007 ($ BILLIONS)
- MAJOR CLASSES OF PLANT DRUGS
- Terpenes and Steroids
- Terpenes
- Steroids
- Alkaloids and Glycosides
- Alkaloids
- Ergot Alkaloids
- Morphine Alkaloids
- Vinca Alkaloids
- Glycosides
- Cardiac Glycosides
- Anthraglycosides
- Phenols
- E. Cava Algae
- Flavonoids
- Resveratrol
- Coumarin
- Catechins
- Proanthocyanidins
- INTELLECTUAL PROPERTY
- PRODUCTION
- MOVING PRODUCTION FORWARD
- ARTEMISININ: A CASE STUDY
- SUPPLY AND LEGAL ISSUES
- TABLE 8 MAJOR PRODUCERS OF RAW MATERIALS FOR PLANT-BASED MEDICINALS
- DRUG DEVELOPMENT AND MANUFACTURE
- TABLE 9 KEY COMPANIES WITH NATURAL PRODUCT LIBRARIES
- CHAPTER 4: MARKET SEGMENTATION
- GEOGRAPHIC SEGMENTATION
- SALES OF PLANT-DERIVED DRUGS BY REGION
- TABLE 10 PLANT-DERIVED DRUG SALES FORECAST BY REGION, THROUGH 2013 (% TOTAL SALES)
- FIGURE 3 GEOGRAPHIC SEGMENTATION FOR PLANT-DERIVED DRUGS, 2008 AND 2013 (%)
- THERAPEUTIC AREA SEGMENTATION
- NUMBER OF PLANT-DERIVED DRUGS BY THERAPEUTIC AREA
- TABLE 11 FDA APPROVED BOTANICAL DRUGS FORECAST THROUGH 2013 (UNITS)
- FIGURE 4 COMPOSITION OF FDA APPROVED BOTANICAL INDICATION FORECAST BY THERAPEUTIC AREA, 2008 AND 2013 (%)*
- Value of Plant-Derived Drugs by Therapeutic Area
- TABLE 12 RELATIVE VALUES OF FDA APPROVED BOTANICAL DRUGS FORECAST BY THERAPUETIC AREA, THROUGH 2013 ($ MILLIONS)
- FIGURE 5 RELATIVE VALUES OF FDA APPROVED BOTANICAL DRUGS FORECAST BY THERAPEUTIC AREA, 2008 AND 2013 (%)
- CHAPTER 5: THERAPEUTIC AREAS IN DETAIL FOR PLANT-DERIVED AND BOTANICAL DRUGS, THROUGH 2013
- HORMONE THERAPY AND METABOLISM APPLICATIONS
- TABLE 13 PLANT-DERIVED HORMONE THERAPY AND METABOLISM DRUGS IN LATE STAGE DEVELOPMENT
- INFECTIOUS DISEASE APPLICATIONS
- TABLE 14 PLANT-DERIVED INFECTIOUS DISEASE DRUGS IN LATE STAGE DEVELOPMENT
- PAIN AND CENTRAL NERVOUS SYSTEM DISEASE APPLICATIONS
- TABLE 15 BRAIN DISORDERS THAT ARE REFRACTORY TO SMALL MOLECULE DRUGS
- TABLE 16 PLANT-DERIVED PAIN AND CNS DRUGS IN LATE STAGE DEVELOPMENT
- CARDIOVASCULAR AND METABOLIC DISEASE
- TABLE 17 PLANT-DERIVED CARDIOVASCULAR AND METABOLIC DRUGS IN LATE STAGE DEVELOPMENT
- RESPIRATORY, INFLAMMATION, AND AUTOIMMUNE
- TABLE 18 PLANT-DERIVED RESPIRATORY, INFLAMMATION, AND AUTOIMMUNE DRUGS IN LATE STAGE DEVELOPMENT
- DERMATOLOGY APPLICATIONS
- TABLE 19 PLANT-DERIVED DERMATOLOGY/WOUND CARE DRUGS IN LATE STAGE DEVELOPMENT
- GASTROINTESTINAL APPLICATIONS
- TABLE 20 PLANT-DERIVED GASTROINTESTINAL DRUGS IN LATE STAGE* DEVELOPMENT )
- ONCOLOGY APPLICATIONS
- TABLE 21 ESTIMATED U.S. CANCER CASES, 2007
- TABLE 22 PLANT-DERIVED ONCOLOGY DRUGS IN LATE STAGE DEVELOPMENT
- TABLE 23 BOTANICAL DRUGS IN LATE STAGE DEVELOPMENT WITH EXPECTED FDA-APPROVED COMMERCIALIZATION, THROUGH 2013*
- CHAPTER 6: COMPANY PROFILES
- ADVANCED LIFE SCIENCES
- ARTECEF B.V.
- AMERICAN ORIENTAL BIOENGINEERING
- ANALYTICON DISCOVERY GMBH
- AVESTHAGEN, LTD.
- BAYER SCHERING
- BIONUMERIK PHARMACEUTICALS, INC.
- BIONOVO, INC.
- BOEHRINGER INGELHEIM
- PHARMATON SA
- BRISTOL MYERS SQUIBB
- CARDAX PHARMACEUTICALS
- CHONG KUN DANG PHARMACEUTICAL CORPORATION
- CUBIST PHARMACEUTICALS, INC.
- CURAPHARM, INC.
- EISAI, INC.
- EKOMED, LLC
- ELI LILLY
- FYTOKEM PRODUCTS, INC.
- GALAPAGOS NV
- GLAXOSMITHKLINE
- GLOBAL PHARMATECH, INC.
- GW PHARMACEUTICALS, PLC
- HETEROGENEITY, LLC
- INDENA
- JOHNSON & JOHNSON
- LIFEPHARMS, INC
- LEO PHARMA
- LUPIN, LTD.
- LUPIN PHARMACEUTICALS, INC.
- MADAUS GMBH
- MERA PHARMACEUTICALS, INC.
- MERIDIAN MEDICAL TECHNOLOGIES, INC.
- KING PHARMACEUTICALS, INC. (PARENT COMPANY)
- MERLION PHARMACEUTICALS
- MEDIGENE
- MEDIGENE, INC.
- TABLE 24 MEDIGENE BOTANICAL PIPELINE
- MERCK & CO., INC.
- MICROBIO
- NAPO PHARMACEUTICALS, INC.
- NEUROGESX, INC.
- NOVARTIS INTERNATIONAL AG
- PANACOS
- PHYTOMEDICAL TECHNOLOGIES
- PHYTOMEDICS, INC.
- PFIZER
- POLYPHENON PHARMA
- PHYNOVA
- TABLE 25 PHYNOVA PIPELINE
- PHYTOCEUTICA, INC.
- PHYTOMYCO RESEARCH CORP.
- PHYTOPHARM, PLC
- PIRAMAL ENTERPRISES, LTD.
- PUNISYN PHARMACEUTICALS, LTD.
- RANBAXY LABORATORIES, LTD.
- SANOFI-AVENTIS
- SCHWABE PHARMACEUTICALS
- SEQUOIA SCIENCES, INC.
- SIRTRIS
- SOLVAY PHARMACEUTICALS
- SUNTEN PHYTOTECH CO., LTD.
- TABLE 26 SUNTECH PHYTOTECH PIPELINE
- TASLY PHARMACEUTICALS, INC.
- TCM BIOTECH INTERNATIONAL CORP
- VEDIC LIFESCIENCES PVT., LTD.
- YAUPON THERAPEUTICS
- WYETH PHARMACEUTICALS
- ZHEJIANG KANGLAITE GROUP CO, LTD.
- APPENDIX
- TABLE 27 PLANT-DERIVED DRUGS: THEIR ORIGIN AND ACTIONS
- TABLE 28 USEFUL RESOURCES FOR THE BOTANICAL DRUG INDUSTRY
Share this report
Other tasks Related Markets Biopharmaceuticals Reports Free Alert Me service Receive bi-weekly email alerts on new market research Sign Up Today!
|
